These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23716398)

  • 1. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice.
    Gedicke-Hornung C; Behrens-Gawlik V; Reischmann S; Geertz B; Stimpel D; Weinberger F; Schlossarek S; Précigout G; Braren I; Eschenhagen T; Mearini G; Lorain S; Voit T; Dreyfus PA; Garcia L; Carrier L
    EMBO Mol Med; 2013 Jul; 5(7):1128-45. PubMed ID: 23716398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
    J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
    Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of human myosin-binding protein C3 variants associated with hypertrophic cardiomyopathy reveals exon-specific cardiac phenotypes in zebrafish model.
    Da'as SI; Yalcin HC; Nasrallah GK; Mohamed IA; Nomikos M; Yacoub MH; Fakhro KA
    J Cell Physiol; 2020 Nov; 235(11):7870-7888. PubMed ID: 31943169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
    Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
    J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
    Goyenvalle A; Babbs A; Wright J; Wilkins V; Powell D; Garcia L; Davies KE
    Hum Mol Genet; 2012 Jun; 21(11):2559-71. PubMed ID: 22388933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering U7snRNA gene to reframe transcripts.
    Goyenvalle A
    Methods Mol Biol; 2012; 867():259-71. PubMed ID: 22454067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction.
    Behrens-Gawlik V; Mearini G; Gedicke-Hornung C; Richard P; Carrier L
    Pflugers Arch; 2014 Feb; 466(2):215-23. PubMed ID: 24337823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.
    Vulin A; Barthélémy I; Goyenvalle A; Thibaud JL; Beley C; Griffith G; Benchaouir R; le Hir M; Unterfinger Y; Lorain S; Dreyfus P; Voit T; Carlier P; Blot S; Garcia L
    Mol Ther; 2012 Nov; 20(11):2120-33. PubMed ID: 22968479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Autophagy Ameliorates Cardiomyopathy in
    Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.
    Goto M; Sawamura D; Nishie W; Sakai K; McMillan JR; Akiyama M; Shimizu H
    J Invest Dermatol; 2006 Dec; 126(12):2614-20. PubMed ID: 16778792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
    Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J
    Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
    Marston S; Copeland O; Gehmlich K; Schlossarek S; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):75-80. PubMed ID: 22057632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice.
    Mearini G; Stimpel D; Geertz B; Weinberger F; Krämer E; Schlossarek S; Mourot-Filiatre J; Stoehr A; Dutsch A; Wijnker PJ; Braren I; Katus HA; Müller OJ; Voit T; Eschenhagen T; Carrier L
    Nat Commun; 2014 Dec; 5():5515. PubMed ID: 25463264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The assembly and evaluation of antisense oligonucleotides applied in exon skipping for titin-based mutations in dilated cardiomyopathy.
    Hahn JK; Neupane B; Pradhan K; Zhou Q; Testa L; Pelzl L; Maleck C; Gawaz M; Gramlich M
    J Mol Cell Cardiol; 2019 Jun; 131():12-19. PubMed ID: 30998980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes.
    Tei S; Ishii HT; Mitsuhashi H; Ishiura S
    Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
    Goyenvalle A; Babbs A; van Ommen GJ; Garcia L; Davies KE
    Mol Ther; 2009 Jul; 17(7):1234-40. PubMed ID: 19455105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.
    Pramono ZA; Wee KB; Wang JL; Chen YJ; Xiong QB; Lai PS; Yee WC
    Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.